According to a new 2003 Impact Repo...

According to a new 2003 Impact Report by plumes Center for the contemplation of Drug Development, pharmaceutical companies now have an average total R&D preciousness of $802 million per of recent origin drug entity and $897 million, if the two pre- and postapproval phases are included. (1) Pharmaceutical companies must initiate their clinical trials in an increasingly efficient manner to make secure thorough protocol development, prompt regulatory readiness, high quality, cost-effective close attention initiation training, accurate and efficient cogitation supply delivery, steady enrollment quality data collection,